In lung cancer, CPNE1 acts as a target of miR-335-5p, and the inhibition of CPNE1 could enhance the clinical efficacy of EGFR-tyrosine kinase inhibitors (Tang et al., 2018a). This evidence concerns the gene EGFR and lung carcinoma.